Am J Perinatol 2024; 41(07): 876-878
DOI: 10.1055/a-1787-6785
Original Article

Is Amniocentesis after CVS Risky?

1   Department of Obstetrics and Gynecology, New York Presbyterian Weill Cornell Medical Center, New York
,
Stephen T. Chasen
1   Department of Obstetrics and Gynecology, New York Presbyterian Weill Cornell Medical Center, New York
› Author Affiliations

Abstract

Objective Approximately, 2% of women who undergo chorionic villi sampling (CVS) will subsequently undergo amniocentesis due to placental mosaicism or sampling/laboratory issues. Our objective was to compare obstetric outcomes in women who underwent both procedures with those who had CVS alone.

Study Design Retrospective case-control study of patients with singleton pregnancies undergoing invasive testing from 2010 to 2020 was performed. All women who underwent CVS followed by amniocentesis were compared with a control group who underwent CVS alone matched (2:1) for age and year of pregnancy. Women with pregnancy loss at <16 weeks were excluded from the control group. Pregnancies terminated for genetic abnormalities were excluded. Obstetric outcomes were compared between cases and controls. Student t-test and Fisher's exact test were used for statistical comparison.

Results During the study period 2,539 women underwent CVS, and 66 (2.6%) subsequently underwent amniocentesis. The 66 cases were compared with 132 age-matched controls who underwent CVS alone. Mean maternal age was 36.8 ± 3.4 years, and 43% of women were nulliparous. Amniocentesis was performed due to sampling or laboratory issues in 33% of cases, placental mosaicism in 44%, and further diagnostic testing in 23%. There were no pregnancy losses or stillbirths in either group. Those who had two invasive procedures delivered at similar gestational ages and birthweights and did not have higher rates of adverse outcomes compared with those who underwent CVS alone.

Conclusion Patients considering CVS who are concerned about the possibility that a second invasive procedure could be required should be reassured that this does not appear to be associated with higher rates of adverse outcomes. Due to study size, we cannot exclude the possibility of small differences in uncommon outcomes, such as pregnancy loss or stillbirth.

Key Points

  • Amniocentesis may be recommended after CVS due to mosaicism, sampling issues, or further testing.

  • Amniocentesis after CVS is not associated with pregnancy loss or other adverse outcomes compared.

  • Patients who have both CVS and amniocentesis deliver at similar gestational ages and birthweights.



Publication History

Received: 10 February 2021

Accepted: 18 February 2022

Accepted Manuscript online:
03 March 2022

Article published online:
21 April 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. Ultrasound Obstet Gynecol 2019; 54 (04) 442-451
  • 2 Malvestiti F, Agrati C, Grimi B. et al. Interpreting mosaicism in chorionic villi: results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis. Prenat Diagn 2015; 35 (11) 1117-1127
  • 3 Duryea EL, Hawkins JS, McIntire DD, Casey BM, Leveno KJ. A revised birth weight reference for the United States. Obstet Gynecol 2014; 124 (01) 16-22
  • 4 Silver RK, Wilson RD, Philip J. et al; NICHD EATA TRial Group. Late first-trimester placental disruption and subsequent gestational hypertension/preeclampsia. Obstet Gynecol 2005; 105 (03) 587-592
  • 5 Zimmer J, Schmitz R, Möllers M. et al. Procedure related risk of premature delivery and fetal growth reduction following amniocentesis, transcervical and transabdominal chorionic villus sampling: a retrospective study. J Perinat Med 2019; 47 (08) 811-816
  • 6 Drey EA, Foster DG, Jackson RA, Lee SJ, Cardenas LH, Darney PD. Risk factors associated with presenting for abortion in the second trimester. Obstet Gynecol 2006; 107 (01) 128-135
  • 7 Bakker M, Birnie E, Robles de Medina P, Sollie KM, Pajkrt E, Bilardo CM. Total pregnancy loss after chorionic villus sampling and amniocentesis: a cohort study. Ultrasound Obstet Gynecol 2017; 49 (05) 599-606
  • 8 Salsi G, Grati FR, Bellussi F. et al. Risk of fetal loss in pregnancies undergoing midtrimester amniocentesis after inconclusive chorionic villus sampling. Fetal Diagn Ther 2019; 46 (03) 149-152